Mar­ket­ingRx roundup: Aduhelm can’t get trac­tion with docs; Pfiz­er press­es vac­cine ef­fort dur­ing NFL play­offs

While much of the phar­ma in­dus­try’s at­ten­tion piv­ot­ed to CMS’ pre­lim­i­nary de­ci­sion last week to on­ly cov­er Bio­gen’s con­tro­ver­sial Alzheimer’s drug Aduhelm in clin­i­cal tri­als and its ef­fect on pre­scrib­ing, neu­rol­o­gists were al­ready hes­i­tant.

Spher­ix Glob­al In­sights has been track­ing neu­rol­o­gists’ per­cep­tion of Aduhelm. Its lat­est six-month sur­vey, tak­en be­fore the CMS de­ci­sion, found that while now most neu­rol­o­gists have had in­ter­ac­tions with Aduhelm sales reps, the ma­jor­i­ty of neu­rol­o­gists are still not ac­tive­ly rec­om­mend­ing the drug.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN